Clinical efficacy and safety of tirofiban in the treatment of patients who received percutaneous coronary intervention
- VernacularTitle:替罗非班早期用于经皮冠状动脉介入治疗的疗效与安全性
- Author:
Kuan WANG
1
;
Dong WANG
;
Liu-Ying ZHENG
;
Guo-Xing ZUO
;
Ming-Hui ZHANG
;
Xin-Ping DU
Author Information
1. 天津市第五中心医院 心内科
- Keywords:
tirofiban;
percutaneous coronary intervention;
myocardial enzyme
- From:
The Chinese Journal of Clinical Pharmacology
2014;(5):397-398,413
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of tirofiban in the treatment of patients who received percutaneous coronary intervention( PCI).Methods Eighty-seven patients with acute coro-nary syndrome treated with PCI were recruited from Feb 2011 to Sep 2013 prospectively.They were randomly divided into treatment group ( n=41 ) and control group ( n=46 ).Based on the regular anticoagulant therapy , patients in the treatment group were given tirofiban 10 mg· kg-1 immediately at the early time of pre -PCI, followed by 0.15μg· kg -1 · min -1 intravenous infusion until 36 hours after PCI.Patients in the control group were only given the regular anticoagulant therapy at the early time of pre-PCI.And the major adverse cardiovascular events (MACE), myocardial enzymes and complication of the two groups were observed in the two groups.Results The rate of MACE (9.8%, 4/41) in treatment group were much lower than that in the control group (26.1%, 12/46) ( P<0.05 ).The myocardial enzyme indicators of 24 hours after PCI was lower than that in the control group;but there was no difference in bleeding complications between the two groups ( P>0.05 ) . Conclusion MACE can be significantly decreased in patients who were treated with PCI by using tirofiban in the emergency department and tiro-fiban does not increase the risks to develop bleeding complications.
